Hanwha Defence Australia (HDA) and Hanwha Systems have signed a teaming agreement with RF communication technology specialist GME at the Avalon Air Show 2025 this week. According to a statement from HDA, the agreement builds on the memorandum of understanding signed at the 2024 MilCIS conference in November last year. With the body of work…
Radio frequency communications specialist GME has announced its acquisition of defence electronics company Eylex. In a statement on Wednesday, GME said the acquisition represented “full ownership and management control” of Eylex, and will boost its “innovation opportunities and assist in its ongoing diversification efforts” within the “defence, security and resilience sectors”. The value of the…
Australian electronics manufacturer GME is linking with Korea’s Hanwha Defence Australia (HDA) and Hanwha Systems through a Memorandum of Understanding (MoU) that brings together leading command, control, communications, computers, and intelligence (C4I) capabilities . Signed at the annual Military Communications and Information Systems (MilCIS) Conference in Canberra, the agreement will see the three parties working…
Electronics business GME has released the new TX6165 range of 5-watt UHF CB (citizen band) radios. In a statement on Monday, the company said the range offers class-leading features including a “large, clear LCD display, 2-Watt speaker and a user-programmable button” as well as 5-Watt transmission power and an IP67 ingress-protection rating. It described the…
GME launches handheld UHF CB radio Australian-owned communications manufacturer GME has launched its Australian made XRS-660 Handheld UHF CB Radio (pictured.) The radio enables people to stay in touch, even in mobile phone black spot areas, with only 27 per cent of the Australian landmass covered by mobile phone reception. The XRS-660 is the first…
Viraleze shows efficacy in Covid-19 patients – Starpharma Starpharma’s Viraleze antiviral nasal spray has demonstrated antiviral efficacy in a placebo-controlled study in participants with Covid-19. Viraleze achieved a statistically significant reduction in SARS-CoV-2 viral load, in the cohort of participants aged 45 and over. Viral load in the nose was reduced by 80 percent less…
